Program
HB0056
A development code.
Its studies are mostly in Idiopathic Pulmonary Fibrosis · Asthma, led by Shanghai Huaota Biopharmaceutical.
Furthest: phase 2, since Sep 5, 20253 company-led studies, 2 open or runningNext primary completion: Aug 1, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai Huaota Biopharmaceutical | 32 open or running | phase 2since Sep 5, 2025 | Sep 23, 2024 | Aug 1, 2027phase 2 · NCT07899996 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 23, 2024First study: phase 1 study in HealthyFirst studyNCT06612970 · 46 enrolled · New Zealand
- Sep 5, 2025Phase 2 study in AsthmaNCT07899996 · 160 planned · China
- Oct 27, 2026Phase 2 study in Idiopathic Pulmonary FibrosisNCT07909655 · 75 planned · China
Ahead
- Aug 1, 2027Primary completion: phase 2 study in AsthmaNCT07899996
- Jan 2028Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisNCT07909655
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07909655Idiopathic Pulmonary Fibrosis · China | 2 | Not yet recruiting | Jan 2028 | 75 |
| NCT07899996Asthma · China | 2 | Recruiting | Aug 1, 2027 | 160 |
| NCT06612970Healthy · New Zealand | 1 | Completed | Jun 13, 2025 | 46 |
How it is read
Names in the registry
- “HB0056”, 4 entries
Codes read as this program: HB0056.
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 1 study
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.